Sign in Sign up for free

Last updated: 20 June 2022 at 4:41pm EST

Blake Wise Net Worth



Mr. Wise CALA stock SEC Form 4 insiders trading

Blake has made over 8 trades of the Calithera Biosciences Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 3,771 units of CALA stock worth $3,356 on 21 February 2019.

The largest trade he's ever made was exercising 35,363 units of Calithera Biosciences Inc stock on 23 August 2017 worth over $129,429. On average, Blake trades about 2,834 units every 46 days since 2016. As of 21 February 2019 he still owns at least 505,650 units of Calithera Biosciences Inc stock.

You can see the complete history of Mr. Wise stock trades at the bottom of the page.





Blake Wise biography

Blake Wise serves as Independent Director of the Company. He has served as a member of our board of directors since September 2017. Since January 2018, Mr. Wise has served as Chief Executive Officer and a member of the board of directors of Achaogen, a biopharmaceutical company developing innovative antibacterials. Mr. Wise joined Achaogen as Chief Operating Officer in 2015 and, in February 2017, he was also appointed President. Prior to joining Achaogen, Mr. Wise served as Vice President, Cross BioOncology at Genentech, where he led cross-portfolio oncology initiatives, including key account management, marketing, managed markets, companion diagnostics, pipeline commercialization, and long-term oncology strategy. Mr. Wise also held several other leadership positions at Genentech including Senior Director, Franchise Head and Life Cycle Leader of the Lytics franchise and as a Sales Director in BioOncology, Marketing Director in Cystic Fibrosis and Immunology, and Interactive Marketing Director. Prior to joining Genentech, Mr. Wise worked in consumer marketing, e-commerce and online marketing in leadership positions at Gap, Inc. and Webvan. Mr. Wise received a Bachelor of Arts degree in Business Economics from University of California, Santa Barbara, and a Masters of Business Administration degree from University of California, Berkeley, Haas School of Business.

What is the salary of Blake Wise?

As the Independent Director of Calithera Biosciences Inc, the total compensation of Blake Wise at Calithera Biosciences Inc is $86,451. There are 12 executives at Calithera Biosciences Inc getting paid more, with Susan Molineaux having the highest compensation of $2,209,840.



How old is Blake Wise?

Blake Wise is 49, he's been the Independent Director of Calithera Biosciences Inc since 2017. There are 14 older and 7 younger executives at Calithera Biosciences Inc. The oldest executive at Calithera Biosciences Inc is H. Ward Wolff, 71, who is the Independent Director.

What's Blake Wise's mailing address?

Blake's mailing address filed with the SEC is C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD. #200, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Calithera Biosciences Inc

Over the last 10 years, insiders at Calithera Biosciences Inc have traded over $23,150,153 worth of Calithera Biosciences Inc stock and bought 7,859,025 units worth $49,155,939 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Partners Gp, L.L.C...., and Deepika Pakianathan. On average, Calithera Biosciences Inc executives and independent directors trade stock every 43 days with the average trade being worth of $8,053. The most recent stock trade was executed by Deepika Pakianathan on 27 January 2023, trading 121,333 units of CALA stock currently worth $47,320.



What does Calithera Biosciences Inc do?

calithera is focused on discovering and developing first-in-class small molecule drugs that slow tumor growth through controlling key metabolic pathways in the tumor and immune cells. tumor metabolism and tumor immunology are promising new interrelated fields for cancer drug discovery. recent clinical successes have demonstrated the potential to slow abnormal cell growth and create fundamentally new therapies for cancer patients. our investigational onco-metabolism medicines take advantage of the different metabolic requirements of tumor cells and cancer-fighting immune cells. calithera’s discovery and development efforts are focused on solid tumors for which new treatments are urgently needed. we are currently developing our lead candidate in phase 2 trials in patients with renal cell carcinoma, triple negative breast cancer. targeting cancer, differently. our onco-metabolism approach brings an enhanced perspective to cancer.



What does Calithera Biosciences Inc's logo look like?

Calithera Biosciences Inc logo

Calithera Biosciences Inc executives and stock owners

Calithera Biosciences Inc executives and other stock owners filed with the SEC include: